Citation: Fohona S. Coulibaly, Danielle N. Thomas, Bi-Botti C. Youan. Anti-HIV lectins and current delivery strategies[J]. AIMS Molecular Science, 2018, 5(1): 96-116. doi: 10.3934/molsci.2018.1.96
[1] | Fangyuan Chen, Rong Yuan . Dynamic behavior of swine influenza transmission during the breed-slaughter process. Mathematical Biosciences and Engineering, 2020, 17(5): 5849-5863. doi: 10.3934/mbe.2020312 |
[2] | Zi Sang, Zhipeng Qiu, Xiefei Yan, Yun Zou . Assessing the effect of non-pharmaceutical interventions on containing an emerging disease. Mathematical Biosciences and Engineering, 2012, 9(1): 147-164. doi: 10.3934/mbe.2012.9.147 |
[3] | Rocio Caja Rivera, Shakir Bilal, Edwin Michael . The relation between host competence and vector-feeding preference in a multi-host model: Chagas and Cutaneous Leishmaniasis. Mathematical Biosciences and Engineering, 2020, 17(5): 5561-5583. doi: 10.3934/mbe.2020299 |
[4] | Yinggao Zhou, Jianhong Wu, Min Wu . Optimal isolation strategies of emerging infectious diseases with limited resources. Mathematical Biosciences and Engineering, 2013, 10(5&6): 1691-1701. doi: 10.3934/mbe.2013.10.1691 |
[5] | Robert Stephen Cantrell, Chris Cosner, Yuan Lou . Evolution of dispersal and the ideal free distribution. Mathematical Biosciences and Engineering, 2010, 7(1): 17-36. doi: 10.3934/mbe.2010.7.17 |
[6] | Fangyuan Chen, Rong Yuan . Reconsideration of the plague transmission in perspective of multi-host zoonotic disease model with interspecific interaction. Mathematical Biosciences and Engineering, 2020, 17(5): 4422-4442. doi: 10.3934/mbe.2020244 |
[7] | Kuang-Hui Lin, Yuan Lou, Chih-Wen Shih, Tze-Hung Tsai . Global dynamics for two-species competition in patchy environment. Mathematical Biosciences and Engineering, 2014, 11(4): 947-970. doi: 10.3934/mbe.2014.11.947 |
[8] | Ricardo López-Ruiz, Danièle Fournier-Prunaret . Complex Behavior in a Discrete Coupled Logistic Model for the Symbiotic Interaction of Two Species. Mathematical Biosciences and Engineering, 2004, 1(2): 307-324. doi: 10.3934/mbe.2004.1.307 |
[9] | S.A. Gourley, Yang Kuang . Two-Species Competition with High Dispersal: The Winning Strategy. Mathematical Biosciences and Engineering, 2005, 2(2): 345-362. doi: 10.3934/mbe.2005.2.345 |
[10] | Christian Cortés García . Bifurcations in discontinuous mathematical models with control strategy for a species. Mathematical Biosciences and Engineering, 2022, 19(2): 1536-1558. doi: 10.3934/mbe.2022071 |
In human history, over 70 % of the emerging infectious diseases are zoonoses, which mainly originate from animal reservoirs. Zoonotic pathogens can transmit from animals to humans. And about 75 % of these zoonotic pathogens originate from wildlife [28,3,24]. Wildlife, domestic animals and humans construct the network of pathogen transmission crossing the species barrier. Wildlife and domestic animals play important roles in the transmission of zoonotic pathogens, in spite of the fact that we always neglected them before a zoonosis emerging or reemerging [12,4].
No matter how well the science and technology developed in human society, human is just one kind of animals, even though other animals are not equal to humans in living status. The existence of the humans has changed the relationship between humans and animals due to some anthropogenic factors. Humans domesticated wolf, which was the ancestor of dog, for hunting about tens of thousands of years ago. Later, the intimacy between humans and dogs was increased more and more by natural selection or human selection, to be precise. In the meantime rabies virus existed permanently in human life by dog-human interface maintaining, as dogs were the mainly natural reservoirs of them, especially in Asia[24,32].
Animals are divided into wildlife and domestic animals by human selection [24]. Humans can manage domestic animals in their entire life, but they cannot control wildlife at liberty. At the same time, humans can contact with domestic animals sufficiently, but they have few opportunities to get in touch with wildlife except for some special professions, such as forest conservationists and poachers. As wildlife and domestic animals play different roles in human life, the zoonotic pathogen transmissions in wildlife infection, domestic animal infection and human infection would be in different styles [17,27]. Various mathematical models have been established in the study of zoonoses [26,1,16,31,11,29]. For example, Doctor Saenz and his partners discussed the impact of domestic animal-human interface in pathogen transmission [26] and Doctor Allen constructed several types of mathematical models to reflect the pathogen transmission in wildlife [1].
For pathogen transmission in multiple species, the multi-SIR model can be established as the form [1,17]:
$
{˙Si=Ai−n∑j=1βjiIjSi−μiSi,˙Ii=n∑j=1βjiIjSi−μiIi−γiIi−αiIi,˙Ri=γiIi−μiRi.
$
|
(1) |
The basic reproduction number
For wildlife, they are always the origin of animal-borne zoonoses [24,12]. The pathogen transmission from wildlife to humans is often neglected due to geographic distance between them, but the globalization and urbanization has shortened this distance. The linkage between wildlife and humans is established with anthropogenic land expanding[24]. And pathogens parasitized in different species could be transmitted to others crossing species barrier by this linkage. But for emerging zoonoses, wildlife play as the only role of natural reservoirs. The pathogen transmission from domestic animals to wildlife or from humans to wildlife could not cause emerging zoonoses. Because the pathogens parasitized in humans or domestic animals have already existed for a period of time, which could be not defined as an emerging event even if the pathogens might transmit back to humans. For example, Severe Acute Respiratory Syndromes (SARS) is defined as an emerging zoonosis, which originate from Rhinolophus, then transmit via palm civets as intermediate host to humans [8]. But for mycobacterium tuberculosis, taking humans as their reservoirs, it could not give rise to an emerging zoonosis even if it had opportunities to infect other animals [20].
That is to say, for wildlife, the zoonotic pathogens could transmit in them,
For the relationship between animals and humans, we assume that not all of people could have opportunities to be infected from animals. Live animals are the mainly origin of zoonotic pathogens and only part of people could contact with them including CAFO (Confined Animal Feeding Operation) workers and hunters [26]. We also take the human population heterogeneity into consideration in this paper. The human population is classified into two groups: high risk group and low risk group. High risk group has the opportunities to contact with infected animals sufficiently. But low risk group are the others. That is, high risk group can get pathogens from animals and humans, but low risk group from humans only. The emerging zoonotic pathogen transmission can be described in FIGURE 1.
Emerging zoonotic pathogen transmission from wildlife, to domestic animals, to humans can be described as the model (2).
$
{˙SW = AW−βWWIWSW−μWSW,˙IW=βWWIWSW−(μW+γW+αW)IW,˙RW=γWIW−μWRW,˙SD=AD−(βWDIW+βDDID)SD−μDSD,˙ID=(βWDIW+βDDID)SD−(γD+αD+μD)ID,˙RD=γDID−μDRD,˙SHH = AHH−[βWHIW+βDHID+βHH(IHH+ILH)]SHH−μHSHH,˙IHH=[βWHIW+βDHID+βHH(IHH+ILH)]SHH −(γH+αH+μH)IHH,˙RHH=γHIHH−μHRHH,˙SLH = ALH−βHH(IHH+ILH)SLH−μHSLH,˙ILH=βHH(IHH+ILH)SLH−(γH+αH+μH)ILH,˙RLH=γHILH−μHRLH.
$
|
(2) |
The basic model has been established to reflect the pathogen transmission from wildlife, to domestic animals, to humans as model (2). Next step, we take the isolation and slaughter strategies into consideration [22,23,8,31,2,25,18]. For wildlife, it is difficult to control them when a zoonosis is emerging. Lethal control, vaccination and fencing (physical barriers) are the primary approaches to limit the number of susceptibles in wildlife. In this paper, we take lethal control and fencing (physical barriers) as the strategies to compare the similar isolation and slaughter strategies in emerging zoonotic pathogen transmission.
$
{˙SW = AW−βWWIWSW−(μW+δS)SW,˙IW=βWWIWSW−(μW+γW+αW+δI)IW,˙RW=γWIW−(μW+δR)RW,˙SD=AD−((1−θD)βWDIW+βDDID)SD−μDSD,˙ID=((1−θD)βWDIW+βDDID)SD−(γD+αD+μD)ID,˙RD=γDID−μDRD,˙SHH = AHH−[(1−θH)βWHIW+βDHID+βHH(IHH+ILH)]SHH −μHSHH,˙IHH=[(1−θH)βWHIW+βDHID+βHH(IHH+ILH)]SHH −(γH+αH+μH)IHH,˙RHH=γHIHH−μHRHH,˙SLH = ALH−βHH(IHH+ILH)SLH−μHSLH,˙ILH=βHH(IHH+ILH)SLH−(γH+αH+μH)ILH,˙RLH=γHILH−μHRLH.
$
|
(3) |
For domestic animals, we can manage them in their entire lives. It is no need to slaughter all of the susceptibles in domestic animals. We can quarantine all of the domestic animals, then isolate susceptibles and slaughter infectives.
$
{˙SD=AD−(βWDIW+βDDID)SD−μDSD,˙ID=(βWDIW+βDDID)SD−(γD+αD+μD+ΔI)ID,˙RD=γDID−μDRD,˙SHH = AHH−[βWHIW+(1−ΘH)βDHID+βHH(IHH+ILH)]SHH −μHSHH,˙IHH=[βWHIW+(1−ΘH)βDHID+βHH(IHH+ILH)]SHH −(γH+αH+μH)IHH,˙RHH=γHIHH−μHRHH,˙SLH = ALH−βHH(IHH+ILH)SLH−μHSLH,˙ILH=βHH(IHH+ILH)SLH−(γH+αH+μH)ILH,˙RLH=γHILH−μHRLH.
$
|
(4) |
For humans, we could not 'slaughter' anyone no matter how serious they were infected with some kind of zoonoses. The quarantine and isolation may be the best method to limit the pathogen transmission except for vaccination. But the effect of quarantine and isolation strategies in humans are different from animals. For taking isolation strategies in animals, it is the susceptible humans, who are afraid of getting infected, to take the initiative and get away from susceptible animals. So the per capita incidence rate from animals to humans,
$
{˙SHH = AHH−[βWHIW+βDHID+βHH(IHH+ILH)]SHH −μHSHH−φ(I)SHH+γH1OHH1,˙OHH1=φ(I)SHH−γH1OHH1−μHOHH1,˙IHH=[βWHIW+βDHID+βHH(IHH+ILH)]SHH −(γH+αH+μH+σ)IHH,˙OHH2=σIHH−γH2OHH2−μHOHH2,˙RHH=γHIHH+γH2OHH2−μHRHH,˙SLH = ALH−βHH(IHH+ILH)SLH−μHSLH −φ(I)SLH+γH1OLH1,˙OLH1=φ(I)SLH−γH1OLH1−μHOLH1,˙ILH=βHH(IHH+ILH)SLH−(γH+αH+μH+σ)ILH,˙OLH2=σILH−γH2OLH2−μHOLH2,˙RLH=γHILH+γH2OLH2−μHRLH.
$
|
(5) |
In conclusion, we can get the isolation and slaughter strategies controlling model by (3), (4) and (5) in wildlife, domestic animals and humans as the form:
$
{˙SW = AW−βWWIWSW−(μW+εWδS)SW,˙IW=βWWIWSW−(μW+γW+αW+εWδI)IW,˙RW=γWIW−(μW+εWδR)RW,˙SD=AD−((1−εWθD)βWDIW+βDDID)SD−μDSD,˙ID=((1−εWθD)βWDIW+βDDID)SD −(γD+αD+μD+εDΔI)ID,˙RD=γDID−μDRD,˙SHH = AHH−[(1−εWθH)βWHIW+(1−εDΘH)βDHID+βHH(IHH +ILH)]SHH−μHSHH−εHφ(I)SHH+γH1OHH1,˙OHH1=εHφ(I)SHH−γH1OHH1−μHOHH1,˙IHH=[(1−εWθH)βWHIW+(1−εDΘH)βDHID +βHH(IHH+ILH)]SHH−(γH+αH+μH+εHσ)IHH,˙OHH2=εHσIHH−γH2OHH2−μHOHH2,˙RHH=γHIHH+γH2OHH2−μHRHH,˙SLH = ALH−βHH(IHH+ILH)SLH−μHSLH −εHφ(I)SLH+γH1OLH1,˙OLH1=εHφ(I)SLH−γH1OLH1−μHOLH1,˙ILH=βHH(IHH+ILH)SLH−(γH+αH+μH+εHσ)ILH,˙OLH2=εHσILH−γH2OLH2−μHOLH2,˙RLH=γHILH+γH2OLH2−μHRLH.
$
|
(6) |
with Strategy 1,
$
{εW=0,ILH+IHH<IWCεW=1,ILH+IHH≥IWC
$
|
(7) |
Strategy 2,
$
{εD=0,ILH+IHH<IDCεD=1,ILH+IHH≥IDC
$
|
(8) |
Strategy 3,
$
{εH=0,ILH+IHH<IHCεH=1,ILH+IHH≥IHC
$
|
(9) |
The feasible set
Total number of wildlife is
It is difficult for us to take any strategies to control emerging zoonoses in first time. Only the infected of numbers of people would cause our attention to take some strategies to control the infectious disease. So it is assumed that if the number of infectives in human including high risk group and low risk group reached a threshold at
With
In (2), the wildlife class can be separated as
$
{˙SW = AW−βWWIWSW−μWSW,˙IW=βWWIWSW−μWIW−γWIW−αWIW.
$
|
(10) |
We can get the basic reproductive number in wildlife
The disease-free equilibrium is
Theorem 2.1. If
Proof. The next generation matrix of the vector field corresponding to system (10) at
${J_W}({E_{0(W)}}) = \left( {−μW−βWWAWμW0βWWAWμW−μW−γW−αW } \right)$
|
If
Similarly, the next generation matrix at
${J_W}(E_{(W)}^*) = \left( {−βWWˆIW−μW−βWWˆSWβWWˆIWβWWˆSW−μW−γW−αW } \right)$
|
The characteristic equation of
$fW(λ)=λ2+AWβWWμW+γW+αWλ+μW(μW+γW+αW)(AWβWWμW(μW+γW+αW)−1)=0
$
|
If
In (2), the wildlife and domestic animals classes can be separated as
$
{˙SW = AW−βWWIWSW−μWSW,˙IW=βWWIWSW−μWIW−γWIW−αWIW,˙SD = AD−βWDIWSD−βDDIDSD−μDSD,˙ID=βWDIWSD+βDDIDSD−γDID−αDID−μDID.
$
|
(11) |
We can get the basic reproductive number in domestic animals is
The disease-free equilibrium is
Theorem 2.2. If
Proof. There always exists
${J_{WD}}({E_{0(WD)}}) = \left( {JW(E0(W))0∗JD(E0(D)) } \right)$
|
with
${J_D}({E_{0(D)}}) = \left( {−μD−βDDADμD0βDDADμD−μD−γD−αD } \right)$
|
If
In (11), the epidemic equilibrium
$ {A_W} - {\beta _{WW}}{\hat I_W}{\hat S_W} - {\mu _W}{\hat S_W}{\text{ = }}0 $ | (12) |
$ {\beta _{WW}}{\hat I_W}{\hat S_W} - {\mu _W}{\hat I_W} - {\gamma _W}{\hat I_W} - {\alpha _W}{\hat I_W}{\text{ = }}0 $ | (13) |
$ {A_D} - {\beta _{WD}}{\hat I_W}{\hat S_D} - {\beta _{DD}}{\hat I_D}{\hat S_D} - {\mu _D}{\hat S_D}{\text{ = }}0 $ | (14) |
$ {\beta _{WD}}{\hat I_W}{\hat S_D} + {\beta _{DD}}{\hat I_D}{\hat S_D} - {\mu _D}{\hat I_D} - {\gamma _D}{\hat I_D} - {\alpha _D}{\hat I_D}{\text{ = }}0 $ | (15) |
From (12), (13), (14), (15), we can get
${\hat S_W} = \frac{{{\mu _W} + {\gamma _W} + {\alpha _W}}}{{{\beta _{WW}}}}$ |
${\hat I_W} = \frac{{{\mu _W}}}{{{\beta _{WW}}}}(\frac{{{A_W}{\beta _{WW}}}}{{{\mu _W}({\mu _W} + {\gamma _W} + {\alpha _W})}} - 1)$ |
$ˆID = βWDˆIWˆSDμD+γD+αD−βDDˆSD=βWDˆSDμD+γD+αD−βDDˆSD×μWβWW(AWβWWμW(μW+γW+αW)−1) $
|
and
$ \hat S_D = \frac{1}{{2{\mu _D}{\beta _{DD}}}} \nonumber [ {{A_D}{\beta _{DD}} + ({\mu _D} + {\gamma _D} + {\alpha _D})({\mu _D} + {\beta _{WD}}{{\hat I}_W})} ] \\ \nonumber - \frac{1}{{2{\mu _D}{\beta _{DD}}}} [ A_D^2\beta _{DD}^2 + 2{A_D}{\beta _{DD}}({\mu _D} + {\gamma _D} + {\alpha _D})({\beta _{WD}}{{\hat I}_W}\\ - {\mu _D}) + {{({\mu _D} + {\gamma _D} + {\alpha _D})}^2}{{({\mu _D} + {\beta _{WD}}{{\hat I}_W})}^2} ]^\frac{1}{2} $ |
So if
In fact, for
$g1(ˆSD)=μDβDDˆSD2−[ADβDD+(μD+γD+αD)(μD+βWDˆIW)]ˆSD+AD(μD+γD+αD)=0 $
|
If
So we choose
$ \hat S_D = \frac{1}{{2{\mu _D}{\beta _{DD}}}} \nonumber [ {{A_D}{\beta _{DD}} + ({\mu _D} + {\gamma _D} + {\alpha _D})({\mu _D} + {\beta _{WD}}{{\hat I}_W})} ] \\ \nonumber - \frac{1}{{2{\mu _D}{\beta _{DD}}}} [ A_D^2\beta _{DD}^2 + 2{A_D}{\beta _{DD}}({\mu _D} + {\gamma _D} + {\alpha _D})({\beta _{WD}}{{\hat I}_W}\\- {\mu _D}) + {{({\mu _D} + {\gamma _D} + {\alpha _D})}^2}{{({\mu _D} + {\beta _{WD}}{{\hat I}_W})}^2} ]^\frac{1}{2} $ |
to guarantee
The next generation matrix at
${J_{WD}}(E_{(WD)}^*) = \left( {JW(E∗(W))0∗JD(E∗(D)) } \right)$
|
with
${J_D}(E_{(D)}^*) = \left( {−βWDˆIW−βDDˆID−μD−βDDˆSDβWDˆIW+βDDˆIDβDDˆSD−μD−γD−αD } \right)$
|
The characteristic equation of
If
In conclusion, if
The human class in (2) can be separated as the form:
$
{˙SHH = AHH−βWHIWSHH−βDHIDSHH−βHH(IHH+ILH)SHH −μHSHH,˙IHH=βWHIWSHH+βDHIDSHH+βHH(IHH+ILH)SHH−γHIHH −αHIHH−μHIHH,˙SLH = ALH−βHH(IHH+ILH)SLH−μHSLH,˙ILH=βHH(IHH+ILH)SLH−γHILH−αHILH−μHILH.
$
|
(16) |
There always exists disease-free equilibrium
The next generation matrix at
${J_{WDH}}({E_{0(WDH)}}) = \left( {JW(E0(W))00∗JD(E0(D))0∗∗JH(E0(H)) } \right)$
|
with
$JH(E0(H))=(−μH−βHHAHHμH0−βHHAHHμH0βHHAHHμH−μH−γH−αH0βHHAHHμH0−βHHALHμH−μH−βHHALHμH0βHHALHμH0βHHALHμH−μH−γH−αH) $
|
The characteristic equation of
If there is
At the same time, the spectral radius of
Theorem 2.3. If
Proof. The next generation matrix at
${J_{WDH}}({E_{0(WDH)}}) = \left( {JW(E0(W))00∗JD(E0(D))0∗∗JH(E0(H)) } \right).$
|
If
Next we prove the existence of epidemic equilibrium
In (16), the epidemic equilibrium
$ {{\text{A}}_{HH}} - {\beta _{WH}}{\hat I_W}{\hat S_{HH}} - {\beta _{DH}}{\hat I_D}{\hat S_{HH}} - {\beta _{HH}}({\hat I_{HH}} + {\hat I_{LH}}){\hat S_{HH}} - {\mu _H}{\hat S_{HH}}{\text{ = }}0 $ | (17) |
$
βWHˆIWˆSHH+βDHˆIDˆSHH+βHH(ˆIHH+ˆILH)ˆSHH−γHˆIHH−αHˆIHH−μHˆIHH = 0
$
|
(18) |
$ {{\text{A}}_{LH}} - {\beta _{HH}}({\hat I_{HH}} + {\hat I_{LH}}){\hat S_{LH}} - {\mu _H}{\hat S_{LH}}{\text{ = }}0 $ | (19) |
$ {\beta _{HH}}({\hat I_{HH}} + {\hat I_{LH}}){\hat S_{LH}} - {\gamma _H}{\hat I_{LH}} - {\alpha _H}{\hat I_{LH}} - {\mu _H}{\hat I_{LH}}{\text{ = }}0 $ | (20) |
From (17) + (19), (18) + (20), we get
$
AHH+ALH−βWHˆIWˆSHH−βDHˆIDˆSHH−βHH(ˆIHH+ˆILH)(ˆSHH+ˆSLH)−μH(ˆSHH+ˆSLH) = 0
$
|
(21) |
$
βWHˆIWˆSHH+βDHˆIDˆSHH+βHH(ˆIHH+ˆILH)(ˆSHH+ˆSLH)−(γH+αH+μH)(ˆIHH + ˆILH) = 0
$
|
(22) |
It is assumed that
Then we have
$ {{\text{A}}_{HH}} + {{\text{A}}_{LH}} - {\eta _S}{\beta _{WH}}{\hat I_W}{\hat S_H} - {\eta _S}{\beta _{DH}}{\hat I_D}{\hat S_H} - {\beta _{HH}}{\hat I_H}{\hat S_H} - {\mu _H}{\hat S_H}{\text{ = }}0 $ | (23) |
$ {\eta _S}{\beta _{WH}}{\hat I_W}{\hat S_H} + {\eta _S}{\beta _{DH}}{\hat I_D}{\hat S_H} + {\beta _{HH}}{\hat I_H}{\hat S_H} - ({\gamma _H} + {\alpha _H} + {\mu _H}){\hat I_H}{\text{ = }}0 $ | (24) |
From (23), (24), we can get
${\hat I_H}{\text{ = }}\frac{{{\eta _S}{\beta _{WH}}{{\hat I}_W}{{\hat S}_H} + {\eta _S}{\beta _{DH}}{{\hat I}_D}{{\hat S}_H}}}{{{\gamma _H} + {\alpha _H} + {\mu _H} - {\beta _{HH}}{{\hat S}_H}}}$ |
and
$\hat S_H = \frac{1}{2 \mu _H \beta _{HH}} \nonumber [ ( A_{HH}+A_{LH})\beta_{HH}+(\gamma _H + \alpha _H +\mu _H) (\mu _H + \eta _S \beta _{WH} {\hat I}_W \\ +\eta _S \beta _{DH} {\hat I}_D) ] \nonumber - \frac{1}{2 \mu _H \beta _{HH}} [ (A_{HH}+A_{LH})^2\beta_{HH}^2 + 2(A_{HH} +A_{LH})\beta_{HH}\\ (\gamma_H + \alpha_H + \mu_H) (\eta _S \beta _{WH} \hat I_W +\eta _S \beta _{DH} \hat I_D -\mu_H) +(\gamma_H + \alpha_H + \mu_H)^2 \nonumber \\ (\mu_H + \eta _S \beta _{WH} \hat I_W +\eta _S \beta _{DH} \hat I_D )^2 ]^\frac{1}{2} $ |
Similarly to the calculation of Theorem 2.2, we have
$g2(ˆSH)=μHβHHˆSH2+(AHH+ALH)(μH+γH+αH)−[(AHH+ALH)βHH+(μH+γH+αH)(μH+ηSβWHˆIW+ηSβDHˆID)]ˆSH=0 $
|
So if
${J_{WDH}}(E_{(WDH)}^*) = \left( {JW(E∗(W))00∗JD(E∗(D))0∗∗JH(E∗(H)) } \right)$
|
with
${J_H}(E_{(H)}^*) = \left( {J11−βHHˆSHH0−βHHˆSHHJ21J220βHHˆSHH0−βHHˆSLHJ33−βHHˆSLH0βHHˆSLHβHH(ˆIHH+ˆILH)J44 } \right)$
|
$ J_{11}=- {\beta _{WH}}{{\hat I}_W} - {\beta _{DH}}{{\hat I}_D} - {\beta _{HH}}({{\hat I}_{LH}} + {{\hat I}_{LH}}) - {\mu _H} $ |
$ J_{21}={\beta _{WH}}{{\hat I}_W} + {\beta _{DH}}{{\hat I}_D} + {\beta _{HH}}({{\hat I}_{LH}} + {{\hat I}_{LH}}) $ |
$ J_{22}={\beta _{HH}}{{\hat S}_{HH}} - {\gamma _H} - {\alpha _H} - {\mu _H} $ |
$ J_{33}=- {\beta _{HH}}({{\hat I}_{HH}} + {{\hat I}_{LH}}) - {\mu _H} $ |
$ J_{44}={\beta _{HH}}{{\hat S}_{LH}} - {\gamma _H} - {\alpha _H} - {\mu _H} $ |
The characteristic equation of
${f_{H2}}(\lambda ) = {\lambda ^4}{\text{ + }}{a_1}{\lambda ^3} + {a_2}{\lambda ^2}{\text{ + }}{a_3}\lambda {\text{ + }}{a_4} = 0$ |
with
${a_1} = \frac{{{A_{HH}}}}{{{{\hat S}_{HH}}}} + \frac{{{A_{LH}}}}{{{{\hat S}_{LH}}}} - {\beta _{HH}}({\hat S_{HH}} + {\hat S_{LH}}) + 2({\gamma _H} + {\alpha _H} + {\mu _H}),$ |
$a2=(AHHˆSHH+ALHˆSLH)(γH+αH+μH)−μHβHH(ˆSHH+ˆSLH)−β2HHˆSHHˆSLH+(AHHˆSHH+βWHˆIWˆIHHˆSHH+βDHˆIDˆIHHˆSHH+βHHˆILHˆIHHˆSHH)(ALHˆSLH+βHHˆIHHˆILHˆSLH), $
|
$a3=ALHˆSLH(AHHˆSHH+γH+αH+μH)(γH+αH+μH)−μHβHHˆSLH(AHHˆSHH+γH+αH+μH)−βHHˆSHHALHˆSLH(γH+αH+μH)+AHHˆSHH(ALHˆSLH+γH+αH+μH)(γH+αH+μH)−μHβHHˆSHH(ALHˆSLH+γH+αH+μH)−βHHˆSLHAHHˆSHH(γH+αH+μH), $
|
$a4=AHHˆSHHALHˆSLH(γH+αH+μH)2−μHβHH(ˆSHHALHˆSLH+ˆSLHAHHˆSHH)(γH+αH+μH) $
|
It is assumed that
In conclusion, if
From Theorem 2.1, Theorem 2.2 and Theorem 2.3, it is more difficult to satisfy the conditions to control emerging zoonoses with the number of susceptible species increasing. But if there was an epidemic in wildlife with
Next we take Strategy 1, Strategy 2 and Strategy 3 into consideration in order to compare the effects of different isolation and slaughter strategies in wildlife, domestic animals and humans on emerging zoonoses.
Strategy 1.
It is assumed that
$
{˙SW = AW−βWWIWSW−μWSW−δSW,˙IW=βWWIWSW−μWIW−γWIW−αWIW−δIW,˙RW=γWIW−μWRW−δRW,˙SD = AD−(1−θD)βWDIWSD−βDDIDSD−μDSD,˙ID=(1−θD)βWDIWSD+βDDIDSD−γDID−αDID−μDID,˙RD=γDID−μDRD,˙SHH = AHH−(1−θH)βWHIWSHH−βDHIDSHH−βHH(IHH +ILH)SHH−μHSHH,˙IHH=(1−θH)βWHIWSHH+βDHIDSHH+βHH(IHH+ILH)SHH −γHIHH−αHIHH−μHIHH,˙RHH=γHIHH−μHRHH,˙SLH = ALH−βHH(IHH+ILH)SLH−μHSLH,˙ILH=βHH(IHH+ILH)SLH−γHILH−αHILH−μHILH,˙RLH=γHILH−μHRLH.
$
|
(25) |
In (25), we get the control reproductive number in wildlife is
For the epidemic equilibrium of
Theorem 2.4. If
Strategy 2.
In (4), we get the control reproductive number in wildlife is
For the epidemic equilibrium of
In fact,
$
g3(ˆS2D)=μDβDD(ˆS2D)2−[ADβDD+(μD+γD+αD+ΔI)(μD+βWDˆIW)]ˆS2D+AD(μD+γD+αD+ΔI)=0
$
|
So we have
$
g3(ˆSD)=μDβDDˆSD2−[ADβDD+(μD+γD+αD+ΔI)(μD+βWDˆIW)]ˆSD+AD(μD+γD+αD+ΔI)
$
|
If
$
g1(ˆSD)=μDβDDˆSD2−[ADβDD+(μD+γD+αD)(μD+βWDˆIW)]ˆSD+AD(μD+γD+αD)=0 $
|
and
${A_D} - {\beta _{WD}}{\hat I_W}{\hat S_D} - {\beta _{DD}}{\hat I_D}{\hat S_D} - {\mu _D}{\hat S_D}{\text{ = }}0,$ |
we get
$g3(ˆSD)=[ADβDD+(μD+γD+αD)(μD+βWDˆIW)]ˆSD−AD(μD+γD+αD)−[ADβDD+(μD+γD+αD+ΔI)(μD+βWDˆIW)]ˆSD+AD(μD+γD+αD+ΔI)=−ΔI(μD+βWDˆIW)ˆSD+ΔIAD=ΔIβDDˆIDˆSD>0. $
|
Then we get
Theorem 2.5. If
Strategy 3.
If we took quarantine and isolation strategies in humans only, the impact of wildlife and domestic animals in human epidemic would be never changed comparing to no strategy. So we select the human epidemic model (26) from (5) for further analysis. At the same time, we choose
$
{˙SHH = AHH−βWHIWSHH−βDHIDSHH−βHH(IHH+ILH)SHH μHSHH−ρ(IHH+ ILH)SHH+γH1OHH1,˙OHH1=ρ(IHH+ ILH)SHH−γH1OHH1−μHOHH1,˙IHH=βWHIWSHH+βDHIDSHH+βHH(IHH+ILH)SHH −γHIHH−αHIHH−μHIHH−σIHH,˙OHH2=σIHH−γH2OHH2−μHOHH2,˙SLH = ALH−βHH(IHH+ILH)SLH−μHSLH−ρ(IHH+ ILH)SLH +γH1OLH1,˙OLH1=ρ(IHH+ ILH)SLH−γH1OLH1−μHOLH1,˙ILH=βHH(IHH+ILH)SLH−γHILH−αHILH−μHILH−σILH,˙OLH2=σILH−γH2OLH2−μHOLH2.
$
|
(26) |
We get the control reproductive number in humans is:
${R_{3(H)}} = \frac{{({A_{HH}} + {A_{LH}}){\beta _{HH}}}}{{{\mu _H}({\mu _H} + {\gamma _H} + {\alpha _H} + \sigma )}}$ |
Theorem 2.6. If
Strategies | no strategy | Strategy 1 | Strategy 2 | Strategy 3 |
Reproductive number in wildlife | | |||
Reproductive number in domestic animals | | | ||
Reproductive number in humans | | | ||
In this section we take avian influenza epidemic in China as an example to analyze the effects of different strategies on emerging zoonoses. Avian influenza is a kind of zoonoses, which have been prevalent in humans since 150 years ago. Avian influenza virus originated from aquatic birds, and it infected domestic birds by sharing watersheds. Humans can be infected by avian influenza virus via infected domestic birds[11,30,6,9]. But for birds, we cannot get the exact parameters to reflect the virus transmission clearly. So we take some similar data to estimate the process of avian influenza virus transmission approximately (TABLE 2).
Parameter | Definitions | Values | Sources |
birth or immigration rate of wild aquatic birds | 0.137 birds/day | Est. | |
| natural mortality rate of wild aquatic birds | 0.000137/day | [33] |
| recovery rate of wild aquatic birds | 0.25/day | Est. |
| disease-induced mortality rate of wild aquatic birds | 0.0025/day | Est. |
| birth or immigration rate of domestic birds | 48.72 birds/day | [33] |
| natural mortality rate of domestic birds | 0.0058/day | [33] |
| recovery rate of domestic birds | 0.25/day | [26] |
| disease-induced mortality rate of domestic birds | 0.0025/day | Est. |
| birth or immigration rate of humans | 0.07people/day | [23] |
| natural mortality rate of humans | 0.000035/day | [23] |
| recovery rate of humans | 0.33/day | [26, 31] |
| remove rate from isolation compartment to susceptible compartment. | 0.5/day | Est. |
| remove rate from isolation compartment to recovery individual compartment. | 0.5/day | Est. |
| disease-induced mortality rate of humans | 0.0033/day | Est. |
| basic reproductive number of wild aquatic birds | 2 | Est. |
| basic reproductive number of domestic birds | 2 | Est. |
| basic reproductive number of humans | 1.2 | [26] |
| per capita incidence rate from wild aquatic birds to domestic birds | Est. | |
| per capita incidence rate from wild aquatic birds to humans | Est. | |
| per capita incidence rate from domestic birds to humans | Est. |
The number of domestic birds is 4.2 times more than the number of humans in China [7], so we assume that the number of domestic birds is 8400 and the number of humans is 2000 to simplify the calculation. And it is assumed that there are about 1000 wild aquatic birds for no exact data found. And it is assumed that
The avian influenza virus transmission has been shown in model (2), which included wildlife, domestic animals, high risk group and low risk group [10,21,13]. For high risk group and low risk group in humans, there may be shown in different proportion in different areas. Less people are needed to take care of live animals in modern farming than tradition. Few people have opportunities to contact with live animals in some areas, which are the potential hosts of some pathogens in emerging zoonoses. But in some other areas, stock raising is the main economy origin of the residents. More people have to look after live animals to help support the family. The proportion of high risk group and low risk group is higher in these areas than others. Here we choose different proportions of high risk group and low risk group, such as 1:9, 1:3, 1:1, 3:1 and 9:1, to reflect emerging avian influenza prevalence in different areas (FIGURE 2).
From a to e in FIGURE 2, we get that more and more high proportion of humans are infected in the first 90 days. More people would be infected with higher proportion of them having the opportunity to contact with susceptible animals. From FIGURE 3, we get that the incidence rate on epidemic equilibrium is increasing with higher proportion of high risk group in humans. Although the proportion of high risk group in humans would never change the basic reproductive number, it could impact the final prevalence in humans.
The effects of parameters
From Ebola, Hendra, Marburg, SARS to H1N1, H7N9, more and more zoonotic pathogens come into humans. Tens of thousands of people have dead of these zoonoses in the last hundreds of years. Some public health policies have to be established to answer emerging or remerging zoonoses. For different species participating in an emerging zoonosis, different strategies should been taken for controlling. In this paper, we established model (3), model (4) and model (5) to reflect the effects of Strategy 1, Strategy 2 and Strategy3 about isolation and slaughter in emerging zoonoses respectively. Strategy 1 is the controlling measure for wildlife. Strategy 2 is the controlling measure for domestic animals. And Strategy 3 is the controlling measure for humans.
All of the three strategies would change the basic reproductive number to their own control reproductive number. The involvement of Strategy 1, Strategy 2 and Strategy 3 would change the conditions, which determine the zoonoses prevalence or not. At the same time, we conclude that the extinction of zoonoses must satisfy the conditions ensuring all of basic (control) reproductive numbers in different species are less than 1, whether it is taken controlling strategy or not. But if and only if basic (control) reproductive numbers in wildlife is more than 1, the zoonoses might be prevalent in all of the susceptible species.
The stability analysis on models in section 2 reflects the effects of three strategies on control reproductive numbers and equilibriums. In section 3, some numerical simulations show the effects of the three strategies on avian influenza epidemic in different areas in China at beginning. In this paper, we take isolation and slaughter strategies into consideration to study their effects on emerging zoonoses. But the other effective strategies like vaccination are neglected, which could be proposed in a forthcoming paper.
This work was supported by the National Natural Science Foundation of China (11371048).
[1] | Hodder SL, Justman J, Haley DF, et al. (2010) Challenges of a hidden epidemic: HIV prevention among women in the United States. J Acquir Immune Defic Syndr 55 Suppl 2: S69–S73. |
[2] | Shattock RJ, Rosenberg Z (2012) Microbicides: Topical prevention against HIV. Cold Spring Harb Perspect Med 2: a007385. |
[3] | UNAIDS. Available from: http://www.unaids.org/en/resources/documents/2016/Global-AIDS-update-2016. |
[4] |
Swanson MD, Winter HC, Goldstein IJ, et al. (2010) A lectin isolated from bananas is a potent inhibitor of HIV replication. J Biol Chem 285: 8646–8655. doi: 10.1074/jbc.M109.034926
![]() |
[5] | Murphy EM, Greene ME, Mihailovic A, et al. (2006) Was the "ABC" approach (abstinence, being faithful, using condoms) responsible for Uganda's decline in HIV? PLoS Med 3: 1–5. |
[6] | Cohen SA. Available from: https://www.guttmacher.org/gpr/2004/11/promoting-b-abc-its-value-and-limitations-fostering-reproductive-health. |
[7] | Sovran S (2013) Understanding culture and HIV/AIDS in sub-Saharan Africa. Sahara J 10: 32–41. |
[8] |
Reniers G, Watkins S (2010) Polygyny and the spread of HIV in sub-Saharan Africa: A case of benign concurrency. Aids 24: 299–307. doi: 10.1097/QAD.0b013e328333af03
![]() |
[9] |
Helweglarsen M, Collins BE (1994) The UCLA Multidimensional Condom Attitudes Scale: Documenting the complex determinants of condom use in college students. Health Psychol 13: 224–237. doi: 10.1037/0278-6133.13.3.224
![]() |
[10] | UNAIDS. Available from: http://www.unaids.org/globalreport/Global_report.htm. |
[11] |
Qian K, Morris-Natschke SL, Lee KH (2009) HIV entry inhibitors and their potential in HIV therapy. Med Res Rev 29: 369–393. doi: 10.1002/med.20138
![]() |
[12] | Fohona S, Coulibaly BBC (2017) Current status of lectin-based cancer diagnosis and therapy. AIMS Mol Sci 4: 1–27. |
[13] | Hansen TK, Gall MA, Tarnow L, et al. (2007) Mannose-binding lectin and mortality in type 2 diabetes. Arch Intern Med 166: 2007–2013. |
[14] | Guan LZ, Tong Q, Xu J (2015) Elevated serum levels of mannose-binding lectin and diabetic nephropathy in type 2 diabetes. PLoS One 10: 1–10. |
[15] | Losin IE, Shakhnovich RM, Zykov KA, et al. (2014) Cardiovascular diseases and mannose-binding lectin. Kardiologiia 54: 64–70. |
[16] |
Kelsall A, Fitzgerald AJ, Howard CV, et al. (2002) Dietary lectins can stimulate pancreatic growth in the rat. Int J Exp Pathol 83: 203–208. doi: 10.1046/j.1365-2613.2002.00230.x
![]() |
[17] | Hoyem PH, Bruun JM, Pedersen SB, et al. (2012) The effect of weight loss on serum mannose-binding lectin levels. Clin Dev Immunol 2012: 1–5. |
[18] |
Akkouh O, Ng TB, Singh SS, et al. (2015) Lectins with anti-HIV activity: A review. Molecules 20: 648–668. doi: 10.3390/molecules20010648
![]() |
[19] |
Checkley MA, Luttge BG, Freed EO (2011) HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J Mol Biol 410: 582–608. doi: 10.1016/j.jmb.2011.04.042
![]() |
[20] |
Balzarini J, Van LK, Hatse S, et al. (2004) Profile of resistance of human immunodeficiency virus to mannose-specific plant lectins. J Virol 78: 10617–10627. doi: 10.1128/JVI.78.19.10617-10627.2004
![]() |
[21] |
Huskens D, Van LK, Vermeire K, et al. (2007) Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12. Virology 360: 294–304. doi: 10.1016/j.virol.2006.10.027
![]() |
[22] |
Blumenthal R, Durell S, Viard M (2012) HIV entry and envelope glycoprotein-mediated fusion. J Biol Chem 287: 40841–40849. doi: 10.1074/jbc.R112.406272
![]() |
[23] | Wilen CB, Tilton JC, Doms RW (2012) HIV: Cell binding and entry. Cold Spring Harb Perspect Med 2: 1–13 |
[24] |
Ratner L, Haseltine W, Patarca R, et al. (1985) Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 313: 277–284. doi: 10.1038/313277a0
![]() |
[25] |
Allan JS, Coligan JE, Barin F, et al. (1985) Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science 228: 1091–1094. doi: 10.1126/science.2986290
![]() |
[26] |
Montagnier L, Clavel F, Krust B, et al. (1985) Identification and antigenicity of the major envelope glycoprotein of lymphadenopathy-associated virus. Virology 144: 283–289. doi: 10.1016/0042-6822(85)90326-5
![]() |
[27] |
Wainhobson S, Sonigo P, Danos O, Cole S, et al. (1985) Nucleotide sequence of the AIDS virus, LAV. Cell 40: 9–17. doi: 10.1016/0092-8674(85)90303-4
![]() |
[28] |
Mizuochi T, Spellman MW, Larkin M, et al. (1988) Carbohydrate structures of the human-immunodeficiency-virus (HIV) recombinant envelope glycoprotein gp120 produced in Chinese-hamster ovary cells. Biochem J 254: 599–603. doi: 10.1042/bj2540599
![]() |
[29] | Mizuochi T, Spellman MW, Larkin M, et al. (1988) Structural characterization by chromatographic profiling of the oligosaccharides of human immunodeficiency virus (HIV) recombinant envelope glycoprotein gp120 produced in Chinese hamster ovary cells. Biomed Chromatogr 2: 260–270. |
[30] | Mizuochi T, Matthews TJ, Kato M, et al. (1990) Diversity of oligosaccharide structures on the envelope glycoprotein gp120 of human immunodeficiency virus 1 from the lymphoblastoid cell line H9. Presence of complex-type oligosaccharides with bisecting N-acetylglucosamine residues. J Biol Chem 265: 8519–8524. |
[31] | Geyer H, Holschbach C, Hunsmann G, et al. (1988) Carbohydrates of human immunodeficiency virus. Structures of oligosaccharides linked to the envelope glycoprotein 120. J Biol Chem 263: 11760–11767. |
[32] |
Go EP, Hewawasam G, Liao HX, et al. (2011) Characterization of glycosylation profiles of HIV-1 transmitted/founder envelopes by mass spectrometry. J Virol 85: 8270–8284. doi: 10.1128/JVI.05053-11
![]() |
[33] | Bonomelli C, Doores KJ, Dunlop DC, et al. (2011) The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS One 6: 1–7. |
[34] |
Go EP, Herschhorn A, Gu C, et al. (2015) Comparative Analysis of the Glycosylation Profiles of Membrane-Anchored HIV-1 Envelope Glycoprotein Trimers and Soluble gp140. J Virol 89: 8245–8257. doi: 10.1128/JVI.00628-15
![]() |
[35] |
Raska M, Takahashi K, Czernekova L, et al. (2010) Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition. J Biol Chem 285: 20860–20869. doi: 10.1074/jbc.M109.085472
![]() |
[36] |
Zhu X, Borchers C, Bienstock RJ, et al. (2000) Mass spectrometric characterization of the glycosylation pattern of HIV-gp120 expressed in CHO cells. Biochemistry 39: 11194–11204. doi: 10.1021/bi000432m
![]() |
[37] |
Doores KJ, Bonomelli C, Harvey DJ, et al. (2010) Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc Natl Acad Sci U S A 107: 13800–13805. doi: 10.1073/pnas.1006498107
![]() |
[38] | Behrens AJ, Harvey DJ, Milne E, et al. (2017) Molecular Architecture of the Cleavage-Dependent Mannose Patch on a Soluble HIV-1 Envelope Glycoprotein Trimer. J Virol 91: 1–16. |
[39] | Sok D, Doores KJ, Briney B, et al. (2014) Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. Sci Transl Med 6: 1–15. |
[40] | Pritchard LK, Spencer DI, Royle L, et al. (2015) Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies. Nat Commun 6: 1–11. |
[41] |
Coss KP, Vasiljevic S, Pritchard LK, et al. (2016) HIV-1 Glycan Density Drives the Persistence of the Mannose Patch within an Infected Individual. J Virol 90: 11132–11144. doi: 10.1128/JVI.01542-16
![]() |
[42] |
Raska M, Novak J (2010) Involvement of envelope-glycoprotein glycans in HIV-1 biology and infection. Arch Immunol Ther Exp 58: 191–208. doi: 10.1007/s00005-010-0072-3
![]() |
[43] |
Wang SK, Liang PH, Astronomo RD, et al. (2008) Targeting the carbohydrates on HIV-1: Interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN. Proc Natl Acad Sci U S A 105: 3690–3695. doi: 10.1073/pnas.0712326105
![]() |
[44] |
Balzarini J (2005) Targeting the glycans of gp120: A novel approach aimed at the Achilles heel of HIV. Lancet Infect Dis 5: 726–731. doi: 10.1016/S1473-3099(05)70271-1
![]() |
[45] |
Koch M, Pancera M, Kwong PD, et al. (2003) Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology 313: 387–400. doi: 10.1016/S0042-6822(03)00294-0
![]() |
[46] | Rathore U, Saha P, Kesavardhana S, et al. (2017) Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity. J Biol Chem 24: 10197–10219. |
[47] |
Sanders RW, Anken EV, Nabatov AA, et al. (2008) The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion. Retrovirology 5: 1–15. doi: 10.1186/1742-4690-5-1
![]() |
[48] |
Montefiori DC, Jr RW, Mitchell WM (1988) Role of protein N-glycosylation in pathogenesis of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 85: 9248–9252. doi: 10.1073/pnas.85.23.9248
![]() |
[49] |
Francois KO, Balzarini J (2011) The highly conserved glycan at asparagine 260 of HIV-1 gp120 is indispensable for viral entry. J Biol Chem 286: 42900–42910. doi: 10.1074/jbc.M111.274456
![]() |
[50] | Mathys L, Francois KO, Quandte M, et al. (2014) Deletion of the highly conserved N-glycan at Asn260 of HIV-1 gp120 affects folding and lysosomal degradation of gp120, and results in loss of viral infectivity. PLoS One 9: 1–11. |
[51] |
Huang X, Jin W, Hu K, et al. (2012) Highly conserved HIV-1 gp120 glycans proximal to CD4-binding region affect viral infectivity and neutralizing antibody induction. Virology 423: 97–106. doi: 10.1016/j.virol.2011.11.023
![]() |
[52] |
Binley JM, Ban YE, Crooks ET, et al. (2010) Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization. J Virol 84: 5637–5655. doi: 10.1128/JVI.00105-10
![]() |
[53] | Li Y, Luo L, Rasool N, et al. (1993) Glycosylation is necessary for the correct folding of human immunodeficiency virus gp120 in CD4 binding. J Virol 67: 584–588. |
[54] |
Li H, Jr CP, Tuen M, Visciano ML, et al. (2008) Identification of an N-linked glycosylation in the C4 region of HIV-1 envelope gp120 that is critical for recognition of neighboring CD4 T cell epitopes. J Immunol 180: 4011–4021. doi: 10.4049/jimmunol.180.6.4011
![]() |
[55] |
Behrens AJ, Vasiljevic S, Pritchard LK, et al. (2016) Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein. Cell Rep 14: 2695–2706. doi: 10.1016/j.celrep.2016.02.058
![]() |
[56] |
Pritchard LK, Vasiljevic S, Ozorowski G, et al. (2015) Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers. Cell Rep 11: 1604–1613. doi: 10.1016/j.celrep.2015.05.017
![]() |
[57] |
Steckbeck JD, Craigo JK, Barnes CO, et al. (2011) Highly conserved structural properties of the C-terminal tail of HIV-1 gp41 protein despite substantial sequence variation among diverse clades: Implications for functions in viral replication. J Biol Chem 286: 27156–27166. doi: 10.1074/jbc.M111.258855
![]() |
[58] |
Dimonte S, Mercurio F, Svicher V, et al. (2011) Selected amino acid mutations in HIV-1 B subtype gp41 are associated with specific gp120v(3) signatures in the regulation of co-receptor usage. Retrovirology 8: 1–11. doi: 10.1186/1742-4690-8-1
![]() |
[59] |
Perrin C, Fenouillet E, Jones IM (1998) Role of gp41 glycosylation sites in the biological activity of human immunodeficiency virus type 1 envelope glycoprotein. Virology 242: 338–345. doi: 10.1006/viro.1997.9016
![]() |
[60] |
Johnson WE, Sauvron JM, Desrosiers RC (2001) Conserved, N-linked carbohydrates of human immunodeficiency virus type 1 gp41 are largely dispensable for viral replication. J Virol 75: 11426–11436. doi: 10.1128/JVI.75.23.11426-11436.2001
![]() |
[61] | Fenouillet E (1993) La N-glycosylation du VIH: Du modèle expérimental à l'application thérapeutique. J Libbery Eurotext Montrouge 9: 901–906. |
[62] |
Fenouillet E, Jones IM (1995) The glycosylation of human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) is important for the efficient intracellular transport of the envelope precursor gp160. J Gen Virol 76: 1509–1514. doi: 10.1099/0022-1317-76-6-1509
![]() |
[63] | Lee WR, Yu XF, Syu WJ, et al. (1992) Mutational analysis of conserved N-linked glycosylation sites of human immunodeficiency virus type 1 gp41. J Virol 66: 1799–1803. |
[64] | Ma BJ, Alam SM, Go EP, et al. (2011) Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies. PLoS Pathog 7: 1–16. |
[65] |
Wang LX, Song H, Liu S, et al. (2005) Chemoenzymatic synthesis of HIV-1 gp41 glycopeptides: Effects of glycosylation on the anti-HIV activity and alpha-helix bundle-forming ability of peptide C34. Chembiochem 6: 1068–1074. doi: 10.1002/cbic.200400440
![]() |
[66] |
Balzarini J, Van LK, Hatse S, et al. (2005) Carbohydrate-binding agents cause deletions of highly conserved glycosylation sites in HIV GP120: A new therapeutic concept to hit the achilles heel of HIV. J Biol Chem 280: 41005–41014. doi: 10.1074/jbc.M508801200
![]() |
[67] |
Van AE, Sanders RW, Liscaljet IM, et al. (2008) Only five of 10 strictly conserved disulfide bonds are essential for folding and eight for function of the HIV-1 envelope glycoprotein. Mol Biol Cell 19: 4298–4309. doi: 10.1091/mbc.E07-12-1282
![]() |
[68] |
Mathys L, Balzarini J (2014) The role of N-glycans of HIV-1 gp41 in virus infectivity and susceptibility to the suppressive effects of carbohydrate-binding agents. Retrovirology 11: 1–18. doi: 10.1186/1742-4690-11-1
![]() |
[69] | Fenouillet E, Jones I, Powell B, et al. (1993) Functional role of the glycan cluster of the human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) ectodomain. J Virol 67: 150–160. |
[70] |
Yuste E, Bixby J, Lifson J, et al. (2008) Glycosylation of gp41 of simian immunodeficiency virus shields epitopes that can be targets for neutralizing antibodies. J Virol 82: 12472–12486. doi: 10.1128/JVI.01382-08
![]() |
[71] |
Tanaka H, Chiba H, Inokoshi J, et al. (2009) Mechanism by which the lectin actinohivin blocks HIV infection of target cells. Proc Natl Acad Sci U S A 106: 15633–15638. doi: 10.1073/pnas.0907572106
![]() |
[72] |
Hoorelbeke B, Huskens D, Ferir G, et al. (2010) Actinohivin, a broadly neutralizing prokaryotic lectin, inhibits HIV-1 infection by specifically targeting high-mannose-type glycans on the gp120 envelope. Antimicrob Agents Chemother 54: 3287–32301. doi: 10.1128/AAC.00254-10
![]() |
[73] |
Zhang F, Hoque MM, Jiang J, et al. (2014) The characteristic structure of anti-HIV actinohivin in complex with three HMTG D1 chains of HIV-gp120. Chembiochem 15: 2766–2773. doi: 10.1002/cbic.201402352
![]() |
[74] |
Bewley CA, Gustafson KR, Boyd MR, et al. (1998) Solution structure of cyanovirin-N, a potent HIV-inactivating protein. Nat Struct Biol 5: 571–578. doi: 10.1038/828
![]() |
[75] |
Barrientos LG, Louis JM, Ratner DM, et al. (2003) Solution structure of a circular-permuted variant of the potent HIV-inactivating protein cyanovirin-N: Structural basis for protein stability and oligosaccharide interaction. J Mol Biol 325: 211–223. doi: 10.1016/S0022-2836(02)01205-6
![]() |
[76] | Esser MT, Mori T, Mondor I, et al. (1999) Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120. J Virol 73: 4360–4371. |
[77] |
Alexandre KB, Gray ES, Mufhandu H, et al. (2012) The lectins griffithsin, cyanovirin-N and scytovirin inhibit HIV-1 binding to the DC-SIGN receptor and transfer to CD4(+) cells. Virology 423: 175–186. doi: 10.1016/j.virol.2011.12.001
![]() |
[78] |
Buffa V, Stieh D, Mamhood N, et al. (2009) Cyanovirin-N potently inhibits human immunodeficiency virus type 1 infection in cellular and cervical explant models. J Gen Virol 90: 234–243. doi: 10.1099/vir.0.004358-0
![]() |
[79] | Boyd MR, Gustafson KR, Mcmahon JB, et al. (1997) Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: Potential applications to microbicide development. Antimicrob Agents Chemother 41: 1521–1530. |
[80] |
Hu Q, Mahmood N, Shattock RJ (2007) High-mannose-specific deglycosylation of HIV-1 gp120 induced by resistance to cyanovirin-N and the impact on antibody neutralization. Virology 368: 145–154. doi: 10.1016/j.virol.2007.06.029
![]() |
[81] |
Keeffe JR, Gnanapragasam PN, Gillespie SK, et al. (2011) Designed oligomers of cyanovirin-N show enhanced HIV neutralization. Proc Natl Acad Sci U S A 108: 14079–14084. doi: 10.1073/pnas.1108777108
![]() |
[82] |
Dey B, Lerner DL, Lusso P, et al. (2000) Multiple antiviral activities of cyanovirin-N: Blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses. J Virol 74: 4562–4569. doi: 10.1128/JVI.74.10.4562-4569.2000
![]() |
[83] |
Férir G, Huskens D, Noppen S, et al. (2014) Broad anti-HIV activity of the Oscillatoria agardhii agglutinin homologue lectin family. J Antimicrob Chemother 69: 2746–2758. doi: 10.1093/jac/dku220
![]() |
[84] |
Koharudin LM, Gronenborn AM (2011) Structural basis of the anti-HIV activity of the cyanobacterial Oscillatoria Agardhii agglutinin. Structure 19: 1170–1181. doi: 10.1016/j.str.2011.05.010
![]() |
[85] |
Koharudin LM, Furey W, Gronenborn AM (2011) Novel fold and carbohydrate specificity of the potent anti-HIV cyanobacterial lectin from Oscillatoria agardhii. J Biol Chem 286: 1588–1597. doi: 10.1074/jbc.M110.173278
![]() |
[86] |
Carneiro MG, Koharudin LM, Ban D, et al. (2015) Sampling of Glycan-Bound Conformers by the Anti-HIV Lectin Oscillatoria agardhii agglutinin in the Absence of Sugar. Angew Chem 54: 6462–6465. doi: 10.1002/anie.201500213
![]() |
[87] |
Bokesch HR, O'Keefe BR, Mckee TC, et al. (2003) A potent novel anti-HIV protein from the cultured cyanobacterium Scytonema varium. Biochemistry 42: 2578–2584. doi: 10.1021/bi0205698
![]() |
[88] |
Adams EW, Ratner DM, Bokesch HR, et al. (2004) Oligosaccharide and glycoprotein microarrays as tools in HIV glycobiology; glycan-dependent gp120/protein interactions. Chem Biol 11: 875–881. doi: 10.1016/j.chembiol.2004.04.010
![]() |
[89] |
Mcfeeters RL, Xiong C, O'Keefe BR, et al. (2007) The novel fold of scytovirin reveals a new twist for antiviral entry inhibitors. J Mol Biol 369: 451–461. doi: 10.1016/j.jmb.2007.03.030
![]() |
[90] |
Alexandre KB, Gray ES, Lambson BE, et al. (2010) Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin. Virology 402: 187–196. doi: 10.1016/j.virol.2010.03.021
![]() |
[91] |
Williams DC, Lee JY, Cai M, et al. (2005) Crystal structures of the HIV-1 inhibitory cyanobacterial protein MVL free and bound to Man3GlcNAc2: Structural basis for specificity and high-affinity binding to the core pentasaccharide from n-linked oligomannoside. J Biol Chem 280: 29269–29276. doi: 10.1074/jbc.M504642200
![]() |
[92] | Ziółkowska NE, Wlodawer A (2006) Structural studies of algal lectins with anti-HIV activity. Acta Biochim Pol 53: 617–626. |
[93] |
Shahzadulhussan S, Gustchina E, Ghirlando R, et al. (2011) Solution structure of the monovalent lectin microvirin in complex with Man(alpha)(1–2)Man provides a basis for anti-HIV activity with low toxicity. J Biol Chem 286: 20788–20796. doi: 10.1074/jbc.M111.232678
![]() |
[94] |
Huskens D, Ferir G, Vermeire K, et al. (2010) Microvirin, a novel alpha(1,2)-mannose-specific lectin isolated from Microcystis aeruginosa, has anti-HIV-1 activity comparable with that of cyanovirin-N but a much higher safety profile. J Biol Chem 285: 24845–24854. doi: 10.1074/jbc.M110.128546
![]() |
[95] |
López S, Armandugon M, Bastida J, et al. (2003) Anti-human immunodeficiency virus type 1 (HIV-1) activity of lectins from Narcissus species. Planta Med 69: 109–112. doi: 10.1055/s-2003-37715
![]() |
[96] | Müller WEG, Forrest JMS, Chang SH, et al. (1991) Narcissus and Gerardia lectins: Tools for the development of a vaccine against AIDS and a new ELISA to quantify HIV-gp 120. Lectins Cancer 1991: 27–40. |
[97] |
Charan RD, Munro MH, O'Keefe BR, et al. (2000) Isolation and characterization of Myrianthus holstii lectin, a potent HIV-1 inhibitory protein from the plant Myrianthus holstii(1). J Nat Prod 63: 1170–1174. doi: 10.1021/np000039h
![]() |
[98] |
Coulibaly FS, Youan BB (2014) Concanavalin A-polysaccharides binding affinity analysis using a quartz crystal microbalance. Biosens Bioelectron 59: 404–411. doi: 10.1016/j.bios.2014.03.040
![]() |
[99] | Bhattacharyya L, Brewer CF (1989) Interactions of concanavalin A with asparagine-linked glycopeptides. Structure/activity relationships of the binding and precipitation of oligomannose and bisected hybrid-type glycopeptides with concanavalin A. Eur J Biochem 178: 721–726. |
[100] |
Witvrouw M, Fikkert V, Hantson A, et al. (2005) Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A. J Virol 79: 7777–7784. doi: 10.1128/JVI.79.12.7777-7784.2005
![]() |
[101] |
Hansen JE, Nielsen CM, Nielsen C, et al. (1989) Correlation between carbohydrate structures on the envelope glycoprotein gp120 of HIV-1 and HIV-2 and syncytium inhibition with lectins. Aids 3: 635–641. doi: 10.1097/00002030-198910000-00003
![]() |
[102] | Matsui T, Kobayashi S, Yoshida O, et al. (1990) Effects of succinylated concanavalin A on infectivity and syncytial formation of human immunodeficiency virus. Med Microbiol Immunol 179: 225–235. |
[103] |
Pashov A, Macleod S, Saha R, et al. (2005) Concanavalin A binding to HIV envelope protein is less sensitive to mutations in glycosylation sites than monoclonal antibody 2G12. Glycobiology 15: 994–1001. doi: 10.1093/glycob/cwi083
![]() |
[104] |
Swanson MD, Boudreaux DM, Salmon L, et al. (2015) Engineering a therapeutic lectin by uncoupling mitogenicity from antiviral activity. Cell 163: 746–758. doi: 10.1016/j.cell.2015.09.056
![]() |
[105] |
Alexandre KB, Gray ES, Pantophlet R, et al. (2011) Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site. J Virol 85: 9039–9050. doi: 10.1128/JVI.02675-10
![]() |
[106] |
Mori T, O'Keefe BR, Bringans S, et al. (2005) Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. J Biol Chem 280: 9345–9353. doi: 10.1074/jbc.M411122200
![]() |
[107] |
Emau P, Tian B, O'Keefe BR, et al. (2007) Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV microbicide. J Med Primatol 36: 244–253. doi: 10.1111/j.1600-0684.2007.00242.x
![]() |
[108] |
Moulaei T, Alexandre KB, Shenoy SR, et al. (2015) Griffithsin tandemers: Flexible and potent lectin inhibitors of the human immunodeficiency virus. Retrovirology 12: 1–14. doi: 10.1186/s12977-014-0129-1
![]() |
[109] | Zhou X, Liu J, Yang B, et al. (2013) Marine natural products with anti-HIV activities in the last decade. Curr Med Chem 20: 953–973. |
[110] |
Wang JH, Kong J, Li W, et al. (2006) A beta-galactose-specific lectin isolated from the marine worm Chaetopterus variopedatus possesses anti-HIV-1 activity. Comp Biochem Physiol C Toxicol Pharmacol 142: 111–117. doi: 10.1016/j.cbpc.2005.10.019
![]() |
[111] |
Bulgheresi S, Schabussova I, Chen T, et al. (2006) A new C-type lectin similar to the human immunoreceptor DC-SIGN mediates symbiont acquisition by a marine nematode. Appl Environ Microbiol 72: 2950–2956. doi: 10.1128/AEM.72.4.2950-2956.2006
![]() |
[112] |
Nabatov AA, Jong MAWPD, Witte LD, et al. (2008) C-type lectin Mermaid inhibits dendritic cell mediated HIV-1 transmission to CD4+ T cells. Virology 378: 323–328. doi: 10.1016/j.virol.2008.05.025
![]() |
[113] |
Molchanova V, Chikalovets I, Chernikov O, et al. (2007) A new lectin from the sea worm Serpula vermicularis: Isolation, characterization and anti-HIV activity. Comp Biochem Physiol C Toxicol Pharmacol 145: 184–193. doi: 10.1016/j.cbpc.2006.11.012
![]() |
[114] |
Vo TS, Kim SK (2010) Potential anti-HIV agents from marine resources: An overview. Mar Drugs 8: 2871–2892. doi: 10.3390/md8122871
![]() |
[115] |
Mahalingam A, Geonnotti AR, Balzarini J, et al. (2011) Activity and safety of synthetic lectins based on benzoboroxole-functionalized polymers for inhibition of HIV entry. Mol Pharmaceutics 8: 2465–2475. doi: 10.1021/mp2002957
![]() |
[116] |
Berube M, Dowlut M, Hall DG (2008) Benzoboroxoles as efficient glycopyranoside-binding agents in physiological conditions: Structure and selectivity of complex formation. J Org Chem 73: 6471–6479. doi: 10.1021/jo800788s
![]() |
[117] | Trippier PC, Mcguigan C, Balzarini J (2010) Phenylboronic-acid-based carbohydrate binders as antiviral therapeutics: Monophenylboronic acids. Antivir Chem Chemother 20: 249–257. |
[118] | Trippier PC, Balzarini J, Mcguigan C (2011) Phenylboronic-acid-based carbohydrate binders as antiviral therapeutics: Bisphenylboronic acids. Antivir Chem Chemother 21: 129–142. |
[119] | Khan JM, Qadeer A, Ahmad E, et al. (2013) Monomeric banana lectin at acidic pH overrules conformational stability of its native dimeric form. PLoS One 8: 1–12. |
[120] |
Suzuki K, Ohbayashi N, Jiang J, et al. (2012) Crystallographic study of the interaction of the anti-HIV lectin actinohivin with the alpha(1-2)mannobiose moiety of gp120 HMTG. Acta Crystallogr Sect F Struct Biol Cryst Commun 68: 1060–1063. doi: 10.1107/S1744309112031077
![]() |
[121] | Tevibénissan C, Bélec L, Lévy M, et al. (1997) In vivo semen-associated pH neutralization of cervicovaginal secretions. Clin Diagn Lab Immunol 4: 367–374. |
[122] |
Ballerstadt R, Evans C, Mcnichols R, et al. (2006) Concanavalin A for in vivo glucose sensing: A biotoxicity review. Biosens Bioelectron 22: 275–284. doi: 10.1016/j.bios.2006.01.008
![]() |
[123] |
Krauss S, Buttgereit F, Brand MD (1999) Effects of the mitogen concanavalin A on pathways of thymocyte energy metabolism. Biochim Biophys Acta 1412: 129–138. doi: 10.1016/S0005-2728(99)00058-4
![]() |
[124] |
Balzarini J, Laethem KV, Peumans WJ, et al. (2006) Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes. J Virol 80: 8411–8421. doi: 10.1128/JVI.00369-06
![]() |
[125] |
Gavrovicjankulovic M, Poulsen K, Brckalo T, et al. (2008) A novel recombinantly produced banana lectin isoform is a valuable tool for glycoproteomics and a potent modulator of the proliferation response in CD3+, CD4+, and CD8+ populations of human PBMCs. Int J Biochem Cell Biol 40: 929–941. doi: 10.1016/j.biocel.2007.10.033
![]() |
[126] |
Mahalingam A, Geonnotti AR, Balzarini J, et al. (2011) Activity and safety of synthetic lectins based on benzoboroxole-functionalized polymers for inhibition of HIV entry. Mol Pharm 8: 2465–2475. doi: 10.1021/mp2002957
![]() |
[127] |
Lam SK, Ng TB (2011) Lectins: Production and practical applications. Appl Microbiol Biotechnol 89: 45–55. doi: 10.1007/s00253-010-2892-9
![]() |
[128] |
Scanlan CN, Offer J, Zitzmann N, et al. (2007) Exploiting the defensive sugars of HIV-1 for drug and vaccine design. Nature 446: 1038–1045. doi: 10.1038/nature05818
![]() |
[129] | Gupta A, Gupta RK, Gupta GS (2009) Targeting cells for drug and gene delivery: Emerging applications of mannans and mannan binding lectins. J Sci Ind Res 68: 465–483. |
[130] |
Ghazarian H, Idoni B, Oppenheimer SB (2011) A glycobiology review: Carbohydrates, lectins and implications in cancer therapeutics. Acta Histochem 113: 236–247. doi: 10.1016/j.acthis.2010.02.004
![]() |
[131] |
Toda S, Ishii N, Okada E, et al. (1997) HIV-1-specific cell-mediated immune responses induced by DNA vaccination were enhanced by mannan-coated liposomes and inhibited by anti-interferon-gamma antibody. Immunology 92: 111–117. doi: 10.1046/j.1365-2567.1997.00307.x
![]() |
[132] |
Zelensky AN, Gready JE (2005) The C-type lectin-like domain superfamily. FEBS J 272: 6179–6217. doi: 10.1111/j.1742-4658.2005.05031.x
![]() |
[133] |
Cui Z, Hsu CH, Mumper RJ (2003) Physical characterization and macrophage cell uptake of mannan-coated nanoparticles. Drug Dev Ind Pharm 29: 689–700. doi: 10.1081/DDC-120021318
![]() |
[134] |
Espuelas S, Thumann C, Heurtault B, et al. (2008) Influence of ligand valency on the targeting of immature human dendritic cells by mannosylated liposomes. Bioconjugate Chem 19: 2385–2393. doi: 10.1021/bc8002524
![]() |
[135] |
Zhang Q, Su L, Collins J, et al. (2014) Dendritic cell lectin-targeting sentinel-like unimolecular glycoconjugates to release an anti-HIV drug. J Am Chem Soc 136: 4325–4332. doi: 10.1021/ja4131565
![]() |
[136] |
Hong PWP, Flummerfelt KB, Parseval AD, et al. (2002) Human immunodeficiency virus envelope (gp120) binding to DC-SIGN and primary dendritic cells is carbohydrate dependent but does not involve 2G12 or cyanovirin binding sites: Implications for structural analyses of gp120-DC-SIGN binding. J Virol 76: 12855–12865. doi: 10.1128/JVI.76.24.12855-12865.2002
![]() |
[137] |
Cruz LJ, Tacken PJ, Fokkink R, et al. (2010) Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. J Controlled Release 144: 118–126. doi: 10.1016/j.jconrel.2010.02.013
![]() |
[138] |
Ingale J, Stano A, Guenaga J, et al. (2016) High-Density Array of Well-Ordered HIV-1 Spikes on Synthetic Liposomal Nanoparticles Efficiently Activate B Cells. Cell Rep 15: 1986–1999. doi: 10.1016/j.celrep.2016.04.078
![]() |
[139] | He L, Val ND, Morris CD, et al. (2016) Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles. Nat Commun 7: 1–15. |
[140] |
Akashi M, Niikawa T, Serizawa T, et al. (1998) Capture of HIV-1 gp120 and virions by lectin-immobilized polystyrene nanospheres. Bioconjugate Chem 9: 50–53. doi: 10.1021/bc970045y
![]() |
[141] |
Hayakawa T, Kawamura M, Okamoto M, et al. (1998) Concanavalin A-immobilized polystyrene nanospheres capture HIV-1 virions and gp120: Potential approach towards prevention of viral transmission. J Med Virol 56: 327–331. doi: 10.1002/(SICI)1096-9071(199812)56:4<327::AID-JMV7>3.0.CO;2-A
![]() |
[142] | Coulibaly FS, Ezoulin MJM, Purohit SS, et al. (2017) Layer-by-layer engineered microbicide drug delivery system targeting HIV-1 gp120: Physicochemical and biological properties. Mol Pharm 14: 3512–3527. |
[143] |
Takahashi K, Moyo P, Chigweshe L, et al. (2013) Efficacy of recombinant chimeric lectins, consisting of mannose binding lectin and L-ficolin, against influenza A viral infection in mouse model study. Virus Res 178: 495–501. doi: 10.1016/j.virusres.2013.10.001
![]() |
[144] |
Sato Y, Morimoto K, Kubo T, et al. (2015) Entry Inhibition of Influenza Viruses with High Mannose Binding Lectin ESA-2 from the Red Alga Eucheuma serra through the Recognition of Viral Hemagglutinin. Mar Drugs 13: 3454–3465. doi: 10.3390/md13063454
![]() |
[145] |
Kachko A, Loesgen S, Shahzad-Ul-Hussan S, et al. (2013) Inhibition of hepatitis C virus by the cyanobacterial protein Microcystis viridis lectin: Mechanistic differences between the high-mannose specific lectins MVL, CV-N, and GNA. Mol Pharmaceutics 10: 4590–4602. doi: 10.1021/mp400399b
![]() |
[146] |
Gadjeva M, Paludan SR, Thiel S, et al. (2004) Mannan-binding lectin modulates the response to HSV-2 infection. Clin Exp Immunol 138: 304–311. doi: 10.1111/j.1365-2249.2004.02616.x
![]() |
[147] |
Eisen S, Dzwonek A, Klein NJ (2008) Mannose-binding lectin in HIV infection. Future Virol 3: 225–233. doi: 10.2217/17460794.3.3.225
![]() |
[148] |
Ji X, Olinger GG, Aris S, et al. (2005) Mannose-binding lectin binds to Ebola and Marburg envelope glycoproteins, resulting in blocking of virus interaction with DC-SIGN and complement-mediated virus neutralization. J Gen Virol 86: 2535–2542. doi: 10.1099/vir.0.81199-0
![]() |
[149] |
Keyaerts E, Vijgen L, Pannecouque C, et al. (2007) Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle. Antiviral Res 75: 179–187. doi: 10.1016/j.antiviral.2007.03.003
![]() |
[150] |
Hamel R, Dejarnac O, Wichit S, et al. (2015) Biology of Zika Virus Infection in Human Skin Cells. J Virol 89: 8880–8896. doi: 10.1128/JVI.00354-15
![]() |
[151] |
Clement F, Venkatesh YP (2010) Dietary garlic (Allium sativum) lectins, ASA I and ASA II, are highly stable and immunogenic. Int Immunopharmacol 10: 1161–1169. doi: 10.1016/j.intimp.2010.06.022
![]() |
[152] | Lusvarghi S, Bewley CA (2016) Griffithsin: An Antiviral Lectin with Outstanding Therapeutic Potential. Viruses 8: 1–18. |
1. | Yin Li, Ian Robertson, The epidemiology of swine influenza, 2021, 1, 2731-0442, 10.1186/s44149-021-00024-6 | |
2. | Fangyuan Chen, Zoonotic modeling for emerging avian influenza with antigenic variation and (M+1)–patch spatial human movements, 2023, 170, 09600779, 113433, 10.1016/j.chaos.2023.113433 |
Strategies | no strategy | Strategy 1 | Strategy 2 | Strategy 3 |
Reproductive number in wildlife | | |||
Reproductive number in domestic animals | | | ||
Reproductive number in humans | | | ||
Parameter | Definitions | Values | Sources |
birth or immigration rate of wild aquatic birds | 0.137 birds/day | Est. | |
| natural mortality rate of wild aquatic birds | 0.000137/day | [33] |
| recovery rate of wild aquatic birds | 0.25/day | Est. |
| disease-induced mortality rate of wild aquatic birds | 0.0025/day | Est. |
| birth or immigration rate of domestic birds | 48.72 birds/day | [33] |
| natural mortality rate of domestic birds | 0.0058/day | [33] |
| recovery rate of domestic birds | 0.25/day | [26] |
| disease-induced mortality rate of domestic birds | 0.0025/day | Est. |
| birth or immigration rate of humans | 0.07people/day | [23] |
| natural mortality rate of humans | 0.000035/day | [23] |
| recovery rate of humans | 0.33/day | [26, 31] |
| remove rate from isolation compartment to susceptible compartment. | 0.5/day | Est. |
| remove rate from isolation compartment to recovery individual compartment. | 0.5/day | Est. |
| disease-induced mortality rate of humans | 0.0033/day | Est. |
| basic reproductive number of wild aquatic birds | 2 | Est. |
| basic reproductive number of domestic birds | 2 | Est. |
| basic reproductive number of humans | 1.2 | [26] |
| per capita incidence rate from wild aquatic birds to domestic birds | Est. | |
| per capita incidence rate from wild aquatic birds to humans | Est. | |
| per capita incidence rate from domestic birds to humans | Est. |
Strategies | no strategy | Strategy 1 | Strategy 2 | Strategy 3 |
Reproductive number in wildlife | | |||
Reproductive number in domestic animals | | | ||
Reproductive number in humans | | | ||
Parameter | Definitions | Values | Sources |
birth or immigration rate of wild aquatic birds | 0.137 birds/day | Est. | |
| natural mortality rate of wild aquatic birds | 0.000137/day | [33] |
| recovery rate of wild aquatic birds | 0.25/day | Est. |
| disease-induced mortality rate of wild aquatic birds | 0.0025/day | Est. |
| birth or immigration rate of domestic birds | 48.72 birds/day | [33] |
| natural mortality rate of domestic birds | 0.0058/day | [33] |
| recovery rate of domestic birds | 0.25/day | [26] |
| disease-induced mortality rate of domestic birds | 0.0025/day | Est. |
| birth or immigration rate of humans | 0.07people/day | [23] |
| natural mortality rate of humans | 0.000035/day | [23] |
| recovery rate of humans | 0.33/day | [26, 31] |
| remove rate from isolation compartment to susceptible compartment. | 0.5/day | Est. |
| remove rate from isolation compartment to recovery individual compartment. | 0.5/day | Est. |
| disease-induced mortality rate of humans | 0.0033/day | Est. |
| basic reproductive number of wild aquatic birds | 2 | Est. |
| basic reproductive number of domestic birds | 2 | Est. |
| basic reproductive number of humans | 1.2 | [26] |
| per capita incidence rate from wild aquatic birds to domestic birds | Est. | |
| per capita incidence rate from wild aquatic birds to humans | Est. | |
| per capita incidence rate from domestic birds to humans | Est. |